Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 89 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NUDEd|F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3mOEBl Mn3DTWM2OD13LkewOUAh|ryPIB?= NH7UdHgyQDV3OU[xNy=>
KP6.3 M1uzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC0JIQ> NUexSZJ7UUN3ME2xNE41OjhizszNJC=> NVrNd|BWOTh3NUm2NVM>
KP7.7 NF[0UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL1VYk1KGR? NV\rZ3dXUUN3ME21O{BvVSB? NGPa[pgyQDV3OU[xNy=>
KB2P3.4 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUntcFV1PCCm MWnJR|UxRTF{NDDNJC=> NV;p[ZJ7OTh3NUm2NVM>
KB2P1.21 M4DXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi0JIQ> MYTJR|UxRTh7MEegcm0h MljzNVg2PTl4MUO=
U373-MG NELkWpVEgXSxdH;4bYMhSXO|YYm= NYTlWpdDOSEQvF2g MlH5NlQhcA>? NVjGdZYzUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MUSxPFk2PDdzMh?=
T98G NU[5OVR5S3m2b4TvfIlkKEG|c3H5 MoTQNUDPxE1i MXKyOEBp NVPqbJNtUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= NXvRVXRjOTh7NUS3NVI>
U87-MG NGrkRZlEgXSxdH;4bYMhSXO|YYm= MYqxJO69VSB? MVuyOEBp MXLJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M2fLbFE5QTV2N{Gy
UVW Ml3vR5l1d3SxeHnjJGF{e2G7 NWLJTmdzPTByIH7N NF63RlQzPCCq MX\JcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M136SFE5QTV2N{Gy
HeLa MnPQSpVv[3Srb36gRZN{[Xl? MUC1NFAhdk1? MW[0JIg> M1O3TWNifXOnczDhJI1w\GW|dDDk[YxigSCrbjDy[YpwcW6rbnegc4YhemGmaXH0bY9vNWmwZIXj[YQhTE6DIHLy[YFsew>? NUi0W4k3OTh7NUS3NVI>
HeLa NHW3VVVHfW6ldHnvckBCe3OjeR?= MUCxJO69VSB? MWiyOEBp MnXmSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? MYCxPFk2PDdzMh?=
T98G MkP5SpVv[3Srb36gRZN{[Xl? MoXTNUDPxE1i NIrqZ5AzPCCq M2HiRWVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 NV;YTnd4OTh7NUS3NVI>
L3 MYnDfZRwfG:6aXOgRZN{[Xl? NXm1Wmh{PSEQvF2g MkS4PVYhcA>? NGnseY5FVVOR NHrlfHRUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> M1ThWFIxOTJ2NEW5
Granta-519 NX7aT3FIS3m2b4TvfIlkKEG|c3H5 Ml\nOUDPxE1i MmLZPVYhcA>? MorNSG1UVw>? NEntUo1UdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NUO1bnBNOjBzMkS0OVk>
BT NF\xfVJEgXSxdH;4bYMhSXO|YYm= NHXIc|Q2KM7:TTC= MY[5OkBp NW[2PW1MTE2VTx?= MmrTV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MojoNlAyOjR2NUm=
UPN2 Mo\sR5l1d3SxeHnjJGF{e2G7 NEf2VY82KM7:TTC= NYqwPFZZQTZiaB?= M2HJcmROW09? MnnVV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NVrNSWc2OjBzMkS0OVk>
HBL-2 NVXyZlE2S3m2b4TvfIlkKEG|c3H5 MXi1JO69VSB? M4nBWlk3KGh? NYrteHc5TE2VTx?= NYfI[2o4W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NEL5SmwzODF{NES1PS=>
JVM-2 MYHDfZRwfG:6aXOgRZN{[Xl? MXe1JO69VSB? MXG5OkBp M3vHTGROW09? M3PrOXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MYeyNFEzPDR3OR?=
Z138 MmPPR5l1d3SxeHnjJGF{e2G7 M3zSUVUh|ryPIB?= MlrBPVYhcA>? NXrSdXYzTE2VTx?= NVrx[HVnW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NV\mSmNQOjBzMkS0OVk>
RWPE NV3ZZ2V{UW64YYPpeoUhSXO|YYm= M1XBU|I2KM7:TR?= MmXrOFghcA>? NFzCRnVFVVOR M1rtT3Nq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> NXTCZ3FpOjF3N{W4OlU>
VCaP NGXOT5JKdn[jc3n2[UBCe3OjeR?= M363fVI2KM7:TR?= M2fMS|Q5KGh? MUDEUXNQ NX\p[IRCW2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? NInmemczOTV5NUi2OS=>
Mouse H2AX−/− ES Cells NU[4ZVlGS3m2b4TvfIlkKEG|c3H5 M{XITlIvPSEQvF2= NYTiZ4w{OjBiaB?= NFLFPWpUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> NX:1UJJ5OjN|NUW0PFk>
Mouse ATM−/− ES Cells MkHUR5l1d3SxeHnjJGF{e2G7 MWqyMlUh|ryP M{XSZVIxKGh? NEnUeFNUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> NV7OeYViOjN|NUW0PFk>
H1650 M4fDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vGclIxKM7:TR?= NUfYcnFJOTR2IHi= MWHJR|UxRTF3LkS3JO69VQ>? NXrLc3hROjN{M{m4NFk>
H1650PTEN+ M2TsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\McFIxKM7:TR?= M3;qXVE1PCCq MUTJR|UxRTVyLkizJO69VQ>? NIKySWgzOzJ|OUiwPS=>
PC-9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XXeVIxKM7:TR?= NHXye4oyPDRiaB?= NV;UU5RzUUN3ME21Mlg5KM7:TR?= M125blI{OjN7OEC5
PC-9PTEN− MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyyNEDPxE1? NImxfYEyPDRiaB?= M4\YSmlEPTB;Nj61NkDPxE1? M3u1UFI{OjN7OEC5
MDA-MB-231 M4rze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPZeZU2KGSjeR?= NXj0fVRoUUN3ME22Mlkh|ryP NYrT[mt1OjN5NkC0PVY>
MDA-MB-468 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvv[lUyPSCmYYm= M1XN[2lEPTB;NT6wJO69VQ>? NGLne3EzOzd4MES5Oi=>
BT20 NITzZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH4RWhbPSCmYYm= NFHQSYtKSzVyPUeuO{DPxE1? Mm\BNlM4PjB2OU[=
HCC1143 M2q0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX70WVlXPSCmYYm= MkTkTWM2OD1zMT6xJO69VQ>? MXmyN|c3ODR7Nh?=
HCC1937 Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\tOUBl[Xl? MlnJTWM2OD1zMj62JO69VQ>? NHPMd40zOzd4MES5Oi=>
Hs578t MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvrOpg2KGSjeR?= NV;p[4c1UUN3ME21MlYh|ryP NGn3V28zOzd4MES5Oi=>
Hs578t(si) NX\0TXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37OWVUh\GG7 MVrJR|UxRTdwNTFOwG0> M3[5U|I{PzZyNEm2
BT474 M3f5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TjeVUh\GG7 MV7JR|UxRTF7Lkig{txO MXeyN|c3ODR7Nh?=
JIMT1 NFL2[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKzOUBl[Xl? MoPaTWM2OD15Lkeg{txO MoT5NlM4PjB2OU[=
SKBR3 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG1JIRigQ>? NWPUR3ZSUUN3ME2xNU4yKM7:TR?= M1zoeVI{PzZyNEm2
SUM159 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rXWFUh\GG7 M{HVS2lEPTB;ND6yJO69VQ>? MojFNlM4PjB2OU[=
CAMA1 NUPlWpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jMWVUh\GG7 MkXzTWM2OD1zNT64JO69VQ>? NGTwPFAzOzd4MES5Oi=>
MCF7 NVTyUo9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi1JIRigQ>? NV:w[plOUUN3ME21Mlgh|ryP Mke4NlM4PjB2OU[=
T47D NHnjRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK1JIRigQ>? NXi2WJlpUUN3ME25MlYh|ryP MXyyN|c3ODR7Nh?=
HCT116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNFAh|ryP MWm0PEBp MWDEUXNQ MXTJR|UxRTJwNTFOwG0h NYjDWnNtOjR3N{e5OFE>
SW1116 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxNFAh|ryP MYG0PEBp M4LZZ2ROW09? M{nMfGlEPTB;MUCwJO69VQ>? MUiyOFU4Pzl2MR?=
HT29 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P1RVExOCEQvF2= NVzye|lVPDhiaB?= MmLrSG1UVw>? M2LzUmlEPTB;MUSuO{DPxE1? M1Luc|I1PTd5OUSx
LoVo MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPuNVAxKM7:TR?= NYP4dWI{PDhiaB?= NYDBbndJTE2VTx?= M2[2T2lEPTB;MUOuOEDPxE1? NVL0ZndGOjR3N{e5OFE>
HCT-15 NFL4NXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2xNFAh|ryP NYD5[ZdlPDhiaB?= MY\EUXNQ NUTyWGlkUUN3ME2xNEDPxE1? NUO2VYY6OjR3N{e5OFE>
SW48 NEnMfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNFAh|ryP MlniOFghcA>? Ml7vSG1UVw>? MWXJR|UxRTlwNTFOwG0> MmjqNlQ2Pzd7NEG=
C-1 NVW4O4FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnV[moyODBizszN NF7uNGk1QCCq MkW4SG1UVw>? NWPDc3pVUUN3ME23MlYh|ryP MYWyOFU4Pzl2MR?=
RKO Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmxNFAh|ryP NHjTN481QCCq NYS4W3ZkTE2VTx?= Mni0TWM2OD13Lkmg{txO MUGyOFU4Pzl2MR?=
HCT116 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xNFAh|ryP NYLke201PDhiaB?= NVzaSlVFTE2VTx?= NU\tS205WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NEDSWIkzPDV5N{m0NS=>
SW1116 NYLGepJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi2SmUyODBizszN MmjTOFghcA>? MlGySG1UVw>? NWHhVGlKWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= Ml\2NlQ2Pzd7NEG=
HT29 NYrRSooxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomxNVAxKM7:TR?= M3;WOFQ5KGh? MnfhSG1UVw>? NF3EWpdRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NEe4N4kzPDV5N{m0NS=>
LoVo NUXZfpFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rtflExOCEQvF2= MYi0PEBp NUjhS2V5TE2VTx?= NUnY[pA2WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NWnaUmxFOjR3N{e5OFE>
SW48 M{jqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;ONVAxKM7:TR?= MXK0PEBp NUX5eFJJTE2VTx?= NVvpVllnWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MlvLNlQ2Pzd7NEG=
C-1 NGDCc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILZfXQyODBizszN MoWyOFghcA>? NH7pN5dFVVOR M1X1fHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MlLLNlQ2Pzd7NEG=
RKO MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWzNVAxKM7:TR?= M4r2ZlQ5KGh? NU\OS2tTTE2VTx?= M3:4SXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NIrzcYIzPDV5N{m0NS=>
HCT116 NYDYNW1tTnWwY4Tpc44hSXO|YYm= M37jelExKG6P NE\QdmsyOiCq MXrEUXNQ MVHJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? M2j3dlI1PTd5OUSx
HT29 Mle2SpVv[3Srb36gRZN{[Xl? NWTPVGdHOTBibl2= NHj5d2oyOiCq M{DZNGROW09? MmPITY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 M1PDelI1PTd5OUSx
TE-6 NF3URZRHfW6ldHnvckBCe3OjeR?= NHLCVos2KM7:TTC= NVrPNJAxOTJiaB?= NV21[4k2TE2VTx?= MmOyTY5lfWOnczDHNk9OKGG{cnXzeC=> NWXsUnFiOjR{MUmxOlQ>
TE-6 NWfjXllCTnWwY4Tpc44hSXO|YYm= NIrxO402KM7:TTC= MkfFNlQhcA>? Ml;MSG1UVw>? MV\JcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq MnjmNlQzOTlzNkS=
Hep3B M2TkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO0NEDPxE1i NYC0fGNmPzJiaB?= NXPtXYE4TE2VTx?= MW\TfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> M2KxOFI2ODd{N{Wy
Huh7 NFPBdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37tOVQxKM7:TTC= MorRO|IhcA>? M4f0bGROW09? NI\vSppUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? M1HaZ|I2ODd{N{Wy
Hep3B NVnubZY3TnWwY4Tpc44hSXO|YYm= M2m3cFQxKM7:TTC= M4j3WlI1KGh? MUDEUXNQ MYrJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NEP2dokzPTB5Mke1Ni=>
Huh7 MkfqSpVv[3Srb36gRZN{[Xl? M3\1ZVQxKM7:TTC= Mnu1NlQhcA>? NUHVUpF5TE2VTx?= Mo\3TY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NVTYW5hYOjVyN{K3OVI>
Hep3B MVPGeY5kfGmxbjDBd5NigQ>? MYC0NEDPxE1i M1P6WVI1KGh? MnzESG1UVw>? NX3yXZV4UW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR M4TlVFI2ODd{N{Wy
Huh7 NFvhc2pHfW6ldHnvckBCe3OjeR?= MljLOFAh|ryPIB?= MYiyOEBp MWrEUXNQ M{HxSmlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= MnzONlUxPzJ5NUK=
SGC-7901 M363NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[2N|DDqM7:TR?= NXLZWIVIPDhiaB?= M1T5XGROW09? MXTCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi= NVjqblhrOjV5NkewO|Y>
COLO-800 MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT4R4JQUUN3ME2wMlQ1OTZ2IN88US=> MY\TRW5ITVJ?
EoL-1- MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vGfWlEPTB;MD61OlQ1PiEQvF2= Mn\sV2FPT0WU
NCI-H209 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPZdVVYUUN3ME2wMlkyPTV4IN88US=> M{fZdHNCVkeHUh?=
ES1 NI[wSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTiOW1ZUUN3ME2xMlEyPDB6IN88US=> MoXiV2FPT0WU
NKM-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi0Z3lUUUN3ME2xMlI2OzR5IN88US=> NYrwR5pnW0GQR1XS
NTERA-S-cl-D1 NF7TVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVuyeHpkUUN3ME2xMlM{OzRzIN88US=> NGLGZYhUSU6JRWK=
MHH-ES-1 M1TmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXvUY5wUUN3ME2xMlYzODZ5IN88US=> NF:2SnpUSU6JRWK=
ES8 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjSeIhIUUN3ME2xMlczPDF2IN88US=> M2m0VnNCVkeHUh?=
NCI-H720 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrCcmRKSzVyPUKuNlA3QTlizszN M{jISXNCVkeHUh?=
EW-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWiyWItnUUN3ME2yMlI4PTN2IN88US=> M4HJS3NCVkeHUh?=
D-566MG M3zLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Ge2hKSzVyPUKuOFQ2PjhizszN MX;TRW5ITVJ?
697 NULudpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDEVJFKSzVyPUKuPFQyPzNizszN NF3LTXdUSU6JRWK=
ES5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXRV5RPUUN3ME2yMlg5OTh7IN88US=> NV;k[nZoW0GQR1XS
COLO-684 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fITGlEPTB;Mz61NVY6PiEQvF2= M2L5VHNCVkeHUh?=
ML-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHZfXpKSzVyPUOuOlAxPThizszN NV61[4VvW0GQR1XS
MC-IXC Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu1R41KSzVyPUOuOlM{QTNizszN M3fOfXNCVkeHUh?=
DB NYf0cWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LKdWlEPTB;Mz62OVQ1QCEQvF2= NVXtbJJpW0GQR1XS
HCC2218 NYThU5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfsTFVKSzVyPUOuO|MyODNizszN Mkj1V2FPT0WU
NCI-H510A NWnPXJBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHnTWM2OD1|LkiyO|I1KM7:TR?= M3\J[nNCVkeHUh?=
NCI-H526 NVL1N2V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jSOmlEPTB;Mz64Olk2QCEQvF2= MnvTV2FPT0WU
MV-4-11 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDnTWM2OD12LkGzN|M1KM7:TR?= MnLNV2FPT0WU
PA-1 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwMkWyPUDPxE1? NWHGZYJNW0GQR1XS
EW-22 M{HRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRwM{W4OkDPxE1? M3HXVXNCVkeHUh?=
KASUMI-1 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC2TFhKSzVyPUSuOFAyODlizszN MmL0V2FPT0WU
LU-139 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRwN{W4Nlkh|ryP NIrrWIlUSU6JRWK=
SBC-1 NGD6bpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\oO5FKSzVyPUSuPFA6ODhizszN M2fEU3NCVkeHUh?=
H4 NUTTZ49wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXWWWxKSzVyPUSuPFk1PDNizszN MUjTRW5ITVJ?
EW-11 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;ETWM2OD13LkC4NFczKM7:TR?= MXjTRW5ITVJ?
NBsusSR M2nrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\SSWlEPTB;NT6xNlA2PSEQvF2= NF3UVmNUSU6JRWK=
RPMI-8226 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTVwMUWyOFQh|ryP MVLTRW5ITVJ?
DEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjtclRWUUN3ME21MlIxODB4IN88US=> M{HGTHNCVkeHUh?=
ES4 NIjhWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVwNUGzPFkh|ryP MkCyV2FPT0WU
GCT M2nLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzHTWM2OD13LkW2PFU3KM7:TR?= NH7xN5hUSU6JRWK=
NCI-H1048 NV3nPJl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrPVHE1UUN3ME21Mlk4Ojd|IN88US=> MnmxV2FPT0WU
NCI-SNU-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTZwMEKyJO69VQ>? M1\3d3NCVkeHUh?=
ES7 M2Szb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWU2lEPTB;Nj6wN|U4PyEQvF2= MWPTRW5ITVJ?
SW982 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTZwMEmxN|ch|ryP M4\qXHNCVkeHUh?=
L-363 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fjN2lEPTB;Nj6zN|k4PCEQvF2= MnO5V2FPT0WU
HT-1080 NVLnPFQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLGTWM2OD14LkS5Olg{KM7:TR?= NHHze41USU6JRWK=
HAL-01 M3e2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rrbmlEPTB;Nj61NVA6KM7:TR?= M{DpTXNCVkeHUh?=
NB14 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZwNkSwN|kh|ryP NHztVJRUSU6JRWK=
EW-13 NFv0dGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXmS2hZUUN3ME22Mlc4PDJ2IN88US=> MYjTRW5ITVJ?
NY MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZwOUS2NFUh|ryP NGfpdpdUSU6JRWK=
NCI-SNU-5 NXrZWI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYCwUZZEUUN3ME23MlExPDN|IN88US=> Ml7kV2FPT0WU
MS-1 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfRTpBsUUN3ME23MlE4PDl2IN88US=> NWPCRZVYW0GQR1XS
EW-16 M13tSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHFfHpKSzVyPUeuN|E5PjFizszN NE[3TlFUSU6JRWK=
LU-65 NELZXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6SGlEPTB;Nz60PFQyPyEQvF2= NE\VZYtUSU6JRWK=
HGC-27 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn2TZlKSzVyPUeuO|IyPzNizszN MV;TRW5ITVJ?
CTB-1 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTHcnVMUUN3ME23Mlc3OTd3IN88US=> MUnTRW5ITVJ?
5637 M4fEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX1TWM2OD15LkmyPFYh|ryP MV\TRW5ITVJ?
U251 M1fXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHeyZWtKSzVyPUeuPVQxOTZizszN NULEOpM6W0GQR1XS
HOS MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6cWlEPTB;OD6yN|AxPyEQvF2= MkTMV2FPT0WU
DOHH-2 NUHGNW5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPDTWM2OD16LkKzOVgh|ryP MlnCV2FPT0WU
EW-1 NF;zWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DGNGlEPTB;OD6zNFA5QCEQvF2= M1r4b3NCVkeHUh?=
BV-173 NGe1UnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnafFYxUUN3ME24MlU2PTRizszN NYLlNGVkW0GQR1XS
8-MG-BA NIP3VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\PTWM2OD16Lk[4PVg5KM7:TR?= NH;OcI5USU6JRWK=
NB69 M1jSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCxTWM2OD16LkewPVIyKM7:TR?= M1\GdnNCVkeHUh?=
NCI-H69 NUniTo1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTlwOUC5OlEh|ryP NVzDdGZHW0GQR1XS
RS4-11 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFzLkKyNFgh|ryP MVHTRW5ITVJ?
ONS-76 NWr0dGFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFzLkK5OFch|ryP MYrTRW5ITVJ?
SF539 NX\xRY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnETWM2OD1zMT60PFg6KM7:TR?= M4S3WHNCVkeHUh?=
HuO-3N1 NFHPc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFzLkW3PVYh|ryP NEfh[IFUSU6JRWK=
NCI-H1651 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nCeWlEPTB;MUKuN|EyPSEQvF2= NUn1OGREW0GQR1XS
KARPAS-45 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF{LkO3OkDPxE1? NIDsSIRUSU6JRWK=
SK-NEP-1 M1zI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L2cGlEPTB;MUKuOFYxQSEQvF2= MUPTRW5ITVJ?
LAMA-84 M4PubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LW[mlEPTB;MUOuNVA6PSEQvF2= M3;LNXNCVkeHUh?=
NCI-H1155 NH;uPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j6fmlEPTB;MUOuNlg2PiEQvF2= M1nzOHNCVkeHUh?=
CTV-1 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrqTWM2OD1zMz60OFUh|ryP NGm0bWJUSU6JRWK=
QIMR-WIL NXXxbFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF|Lke4NVQh|ryP MWPTRW5ITVJ?
H9 NGXuVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXXN5VRUUN3ME2xN{45PDd3IN88US=> NYDzboNbW0GQR1XS
SK-MEL-1 NHzr[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XLOWlEPTB;MUOuPVM1PyEQvF2= MmTDV2FPT0WU
HD-MY-Z NWDHc5BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrvcZhKSzVyPUG0MlA3OzdizszN NIDKRo1USU6JRWK=
TI-73 NWG1NXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTBb3oyUUN3ME2xOE4zOzV4IN88US=> NEnu[olUSU6JRWK=
JVM-3 NXzNO5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfXTWM2OD1zNT61O|E3KM7:TR?= M4X4O3NCVkeHUh?=
D-247MG NUHz[Y94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS3VnBKSzVyPUG1MlU6OyEQvF2= NGfCeFJUSU6JRWK=
VA-ES-BJ M{XpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK2TWM2OD1zNT62NFk4KM7:TR?= NE\5Z5BUSU6JRWK=
NOS-1 M4HyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LKNGlEPTB;MUWuOlUzOiEQvF2= NV;GNGs5W0GQR1XS
MOLT-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK4XIVKSzVyPUG2Mlc2OiEQvF2= MnWyV2FPT0WU
Mo-T NFH1fGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O5[WlEPTB;MUeuNFg1QSEQvF2= NFnDOY1USU6JRWK=
NCI-H1770 NUXuUHp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\rTWM2OD1zNz6xOVQ{KM7:TR?= NISycVdUSU6JRWK=
COLO-320-HSR M4DXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzGZ|RKSzVyPUG3MlE5OjdizszN MYjTRW5ITVJ?
TE-12 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKyVoNKSzVyPUG3MlcxPTRizszN M{DBfXNCVkeHUh?=
NCI-H82 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvsTWM2OD1zNz64O|I5KM7:TR?= MVTTRW5ITVJ?
NEC8 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:zO3VyUUN3ME2xPE4yOzF4IN88US=> NGDR[lBUSU6JRWK=
HSC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF6Lke0NVQh|ryP MlXUV2FPT0WU
NCI-H1092 NV7G[mtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\heGFKSzVyPUG4Mlc2QTVizszN Mn\QV2FPT0WU
NCI-H292 M4PlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHVcmJKSzVyPUG5MlA1QDlizszN NEnxUopUSU6JRWK=
L-428 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M333bGlEPTB;MUmuOVU6KM7:TR?= MYXTRW5ITVJ?
LU-134-A MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF7LkW3NkDPxE1? M2PneXNCVkeHUh?=
GI-ME-N M4\3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHzTWM2OD1zOT61O|Q4KM7:TR?= M4\MO3NCVkeHUh?=
ALL-PO NUK3OY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\6TWM2OD1zOT61PVczKM7:TR?= M2HwWnNCVkeHUh?=
D-283MED NX\1T3B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEizOpJKSzVyPUG5MlkyPSEQvF2= MYjTRW5ITVJ?
D-423MG NYT3[mV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLRW5FxUUN3ME2xPU46QTZ5IN88US=> M4DWXnNCVkeHUh?=
CAKI-1 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjufJRKSzVyPUKwMlIzOTlizszN MmK4V2FPT0WU
ETK-1 NGi0XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXPcYZGUUN3ME2yNE4zPjF3IN88US=> NHf2VJdUSU6JRWK=
G-402 NFe5fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLRTWM2OD1{MD61N|M1KM7:TR?= MXzTRW5ITVJ?
HL-60 NF\P[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f6SWlEPTB;MkGuNVYyOyEQvF2= MWLTRW5ITVJ?
A2058 M2DiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJzLkS0O|ch|ryP M1;LPHNCVkeHUh?=
CHP-212 NXr2O5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJzLkmwOVEh|ryP M1rkdHNCVkeHUh?=
KY821 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X0XmlEPTB;MkGuPVc2KM7:TR?= NH;ZVnRUSU6JRWK=
TYK-nu M2i5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID2bFBKSzVyPUKyMlA3PTFizszN NV\QSlI1W0GQR1XS
JVM-2 M{DzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTZTWM2OD1{Mj6yPVg{KM7:TR?= NX7WU49OW0GQR1XS
KU812 NGrLXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITPS25KSzVyPUKyMlc{OTJizszN MWrTRW5ITVJ?
MKN28 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfvSG9KSzVyPUKyMlkxOTVizszN MknvV2FPT0WU
ECC10 NWrFXI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHweYtKSzVyPUKzMlc1OSEQvF2= M3zq[nNCVkeHUh?=
BHT-101 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXnTWM2OD1{ND6wNFA5KM7:TR?= MULTRW5ITVJ?
DU-4475 M1\hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ2LkOzN|ch|ryP NFzYcWtUSU6JRWK=
769-P NYLmSnR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPzPXh6UUN3ME2yOE45PDZ4IN88US=> NYjreI1UW0GQR1XS
HEC-1 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJ3LkS0OUDPxE1? MonWV2FPT0WU
MOLT-13 NIS5U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ3LkWzN|Eh|ryP MX;TRW5ITVJ?
8505C NYjjWIw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH5R2ZKSzVyPUK2MlQ6PzdizszN MnvUV2FPT0WU
GB-1 NW\DXJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF33bo1KSzVyPUK2MlcyPzZizszN MlryV2FPT0WU
SF126 M4W1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm2WJZSUUN3ME2yOk44PjR6IN88US=> M3W3ZXNCVkeHUh?=
A4-Fuk M4G3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7RTWM2OD1{Nz6xNlcyKM7:TR?= Mli3V2FPT0WU
OVCAR-8 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPVTWM2OD1{Nz6xOVM6KM7:TR?= NW\HTmJJW0GQR1XS
NCI-H1304 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ5LkW0JO69VQ>? NXLmTItrW0GQR1XS
GR-ST NEXiOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rYR2lEPTB;MkiuNFQ4KM7:TR?= NIDMdI1USU6JRWK=
G-401 NH3aeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJ6LkWwPVYh|ryP NHTJUY9USU6JRWK=
LXF-289 M2XLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\H[IdKSzVyPUK4MlU3PTFizszN MWDTRW5ITVJ?
DBTRG-05MG NGTVPWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjrSoljUUN3ME2yPE46OjB2IN88US=> NXG2XHp6W0GQR1XS
YKG-1 M2nKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknsTWM2OD1{OT64Olgh|ryP MlHtV2FPT0WU
GAMG NV3Hb2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi1OGdEUUN3ME2yPU46QTNizszN MmH3V2FPT0WU
HCT-116 M2nJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNyLkC1OFgh|ryP NGHjTm1USU6JRWK=
S-117 NXLYU3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXVc3dDUUN3ME2zNU4zOjV5IN88US=> MlrXV2FPT0WU
NCI-H1693 NYr4fok6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTN|Lk[1OFIh|ryP NE\zVmNUSU6JRWK=
A427 M1jNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e2bWlEPTB;M{OuPVk4PiEQvF2= MonuV2FPT0WU
HT-29 NU\PSJFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN2Lk[wN|Ih|ryP M3nRNHNCVkeHUh?=
P12-ICHIKAWA M4fINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTN2Lke0PVEh|ryP NYHXN5lUW0GQR1XS
CAL-51 M17HTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X6bGlEPTB;M{WuNFcxQSEQvF2= MlfVV2FPT0WU
Ramos-2G6-4C10 M2PBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrZRWpKSzVyPUO1MlI1OjVizszN MmP2V2FPT0WU
SCH MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L1dmlEPTB;M{[uOFE4PCEQvF2= M1XrOXNCVkeHUh?=
SK-MEL-24 NF[ybJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN4LkmwOFQh|ryP NHjQcFlUSU6JRWK=
SW1573 M3r5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN6LkeyNVYh|ryP M1v6RXNCVkeHUh?=
BALL-1 M2GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DhPGlEPTB;M{muNlEzQSEQvF2= MVzTRW5ITVJ?
BE-13 NUHMSGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn3O3JKSzVyPUO5MlMzQSEQvF2= NY\mUGhRW0GQR1XS
GI-1 NYPrOJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP2TWM2OD1|OT64OlQ4KM7:TR?= M3zp[nNCVkeHUh?=
GOTO NGrlcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;kVo5EUUN3ME2zPU46OTN7IN88US=> NEnTVmxUSU6JRWK=
A673 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRzLkCzOFMh|ryP NHuzflJUSU6JRWK=
KG-1 M{jKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPodmlTUUN3ME20N{4{QTRizszN M4jvNHNCVkeHUh?=
GP5d NGXLZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjiWpVKSzVyPUS0MlA3PjZizszN MnLnV2FPT0WU
MFM-223 NXTjRVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXrTWM2OD12ND6xNlI5KM7:TR?= NUjxOmhFW0GQR1XS
OAW-42 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX6b|Q6UUN3ME20OE4zPjR|IN88US=> NYO5XlFPW0GQR1XS
C8166 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR3LkC4NlIh|ryP M171WnNCVkeHUh?=
LU-99A MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTR4LkGzNlIh|ryP NUDrRpFHW0GQR1XS
NCI-H23 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlizTWM2OD12Nj6xO|g2KM7:TR?= NXnhZm9MW0GQR1XS
HO-1-N-1 NWCwUnlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDnVHBzUUN3ME20O{4xQTl6IN88US=> NEOydm1USU6JRWK=
A3-KAW NV3hdHdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3PTWM2OD12Nz6xNFA4KM7:TR?= NVjWOpIyW0GQR1XS
CGTH-W-1 M2H0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHtXXhKSzVyPUS3MlUxPjlizszN MV\TRW5ITVJ?
DJM-1 NYGwemFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHJTWM2OD12Nz61OFE{KM7:TR?= M4XpfnNCVkeHUh?=
A101D NFPTVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jIXmlEPTB;NEeuOlM2PyEQvF2= NGfWcnNUSU6JRWK=
BB30-HNC NFi1VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDUNXFSUUN3ME20PE4{ODd{IN88US=> NYXTcXRuW0GQR1XS
T98G M{LqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;LTFFQUUN3ME20PE41PjN|IN88US=> Mm\tV2FPT0WU
NCI-H1573 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jvcGlEPTB;NEmuOFQ3OiEQvF2= Mo\HV2FPT0WU
MEG-01 NEf0[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR7Lke0NVEh|ryP NEPCZ5FUSU6JRWK=
WM-115 M2P6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37PdWlEPTB;NEmuPVIzOiEQvF2= MlnjV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03561870 Not yet recruiting Recurrent IDH|Mutant High Grade Glioma Hospices Civils de Lyon December 1 2019 Phase 2
NCT03741426 Not yet recruiting Renal Cell Cancer CCTU- Cancer Theme|University of Cambridge|AstraZeneca|Cancer Research UK|Cambridge University Hospitals NHS Foundation Trust July 25 2019 Phase 2
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System March 1 2019 Phase 1
NCT03740893 Not yet recruiting Breast Neoplasm Institute of Cancer Research United Kingdom|AstraZeneca February 2019 Phase 2
NCT03742895 Not yet recruiting Advanced Solid Neoplasms Merck Sharp & Dohme Corp. December 17 2018 Phase 2
NCT03740165 Not yet recruiting Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms Merck Sharp & Dohme Corp.|European Network for Gynaecological Oncological Trial Groups December 14 2018 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID